Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT)

Maria Ferris, Victoria Norwood, Milena Radeva, Jennifer J. Gassman, Amira Al-Uzri, David Askenazi, Tej Matoo, Maury Pinsk, Amita Sharma, William Smoyer, Jenna Stults, Shefali Vyas, Robert Weiss, Debbie Gipson, Frederick J. Kaskel, Aaron Friedman, Marva Moxey-Mims, Howard Trachtman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identification and recruitment of participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclosporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced difficulty and delays meeting enrollment goals. These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were identified including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 ± 0.8 months); (4) prolonged time between IRB approval and enrollment of the first patient at participating sites (mean 19.6 ± 1.4 months); and (5) reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology.

Original languageEnglish (US)
Pages (from-to)13-20
Number of pages8
JournalClinical and Translational Science
Volume6
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Focal Segmental Glomerulosclerosis
Kidney Diseases
Patient Selection
Randomized Controlled Trials
Research Ethics Committees
Clinical Trials
Mycophenolic Acid
Dexamethasone
Cyclosporine
Patient Advocacy
Logistics
Labels
Nephrology
National Institutes of Health (U.S.)
Health
Multicenter Studies
Testing
Research Personnel

Keywords

  • Clinical trials
  • Kidney
  • Nephrology
  • Pediatrics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease : Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT). / Ferris, Maria; Norwood, Victoria; Radeva, Milena; Gassman, Jennifer J.; Al-Uzri, Amira; Askenazi, David; Matoo, Tej; Pinsk, Maury; Sharma, Amita; Smoyer, William; Stults, Jenna; Vyas, Shefali; Weiss, Robert; Gipson, Debbie; Kaskel, Frederick J.; Friedman, Aaron; Moxey-Mims, Marva; Trachtman, Howard.

In: Clinical and Translational Science, Vol. 6, No. 1, 02.2013, p. 13-20.

Research output: Contribution to journalArticle

Ferris, M, Norwood, V, Radeva, M, Gassman, JJ, Al-Uzri, A, Askenazi, D, Matoo, T, Pinsk, M, Sharma, A, Smoyer, W, Stults, J, Vyas, S, Weiss, R, Gipson, D, Kaskel, FJ, Friedman, A, Moxey-Mims, M & Trachtman, H 2013, 'Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT)', Clinical and Translational Science, vol. 6, no. 1, pp. 13-20. https://doi.org/10.1111/cts.12003
Ferris, Maria ; Norwood, Victoria ; Radeva, Milena ; Gassman, Jennifer J. ; Al-Uzri, Amira ; Askenazi, David ; Matoo, Tej ; Pinsk, Maury ; Sharma, Amita ; Smoyer, William ; Stults, Jenna ; Vyas, Shefali ; Weiss, Robert ; Gipson, Debbie ; Kaskel, Frederick J. ; Friedman, Aaron ; Moxey-Mims, Marva ; Trachtman, Howard. / Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease : Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT). In: Clinical and Translational Science. 2013 ; Vol. 6, No. 1. pp. 13-20.
@article{a6a372b9046d464d919efa7fe7de85a7,
title = "Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT)",
abstract = "We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identification and recruitment of participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclosporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced difficulty and delays meeting enrollment goals. These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were identified including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 ± 0.8 months); (4) prolonged time between IRB approval and enrollment of the first patient at participating sites (mean 19.6 ± 1.4 months); and (5) reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology.",
keywords = "Clinical trials, Kidney, Nephrology, Pediatrics",
author = "Maria Ferris and Victoria Norwood and Milena Radeva and Gassman, {Jennifer J.} and Amira Al-Uzri and David Askenazi and Tej Matoo and Maury Pinsk and Amita Sharma and William Smoyer and Jenna Stults and Shefali Vyas and Robert Weiss and Debbie Gipson and Kaskel, {Frederick J.} and Aaron Friedman and Marva Moxey-Mims and Howard Trachtman",
year = "2013",
month = "2",
doi = "10.1111/cts.12003",
language = "English (US)",
volume = "6",
pages = "13--20",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Patient Recruitment into a Multicenter Randomized Clinical Trial for Kidney Disease

T2 - Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT)

AU - Ferris, Maria

AU - Norwood, Victoria

AU - Radeva, Milena

AU - Gassman, Jennifer J.

AU - Al-Uzri, Amira

AU - Askenazi, David

AU - Matoo, Tej

AU - Pinsk, Maury

AU - Sharma, Amita

AU - Smoyer, William

AU - Stults, Jenna

AU - Vyas, Shefali

AU - Weiss, Robert

AU - Gipson, Debbie

AU - Kaskel, Frederick J.

AU - Friedman, Aaron

AU - Moxey-Mims, Marva

AU - Trachtman, Howard

PY - 2013/2

Y1 - 2013/2

N2 - We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identification and recruitment of participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclosporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced difficulty and delays meeting enrollment goals. These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were identified including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 ± 0.8 months); (4) prolonged time between IRB approval and enrollment of the first patient at participating sites (mean 19.6 ± 1.4 months); and (5) reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology.

AB - We describe the experience of the focal segmental glomerulosclerosis clinical trial (FSGS CT) in the identification and recruitment of participants into the study. This National Institutes of Health funded study, a multicenter, open-label, randomized comparison of cyclosporine versus oral dexamethasone pulses plus mycophenolate mofetil, experienced difficulty and delays meeting enrollment goals. These problems occurred despite the support of patient advocacy groups and aggressive recruitment strategies. Multiple barriers were identified including: (1) inaccurate estimates of the number of potential incident FSGS patients at participating centers; (2) delays in securing one of the test agents; (3) prolonged time between IRB approval and execution of a subcontract (mean 7.5 ± 0.8 months); (4) prolonged time between IRB approval and enrollment of the first patient at participating sites (mean 19.6 ± 1.4 months); and (5) reorganization of clinical coordinating core infrastructure to align resources with enrollment. A Web-based anonymous survey of site investigators revealed site-related barriers to patient recruitment. The value of a variety of recruitment tools was of marginal utility in facilitating patient enrollment. We conclude that improvements in the logistics of study approval and regulatory start-up and testing of promising novel agents are important factors in promoting enrollment into randomized clinical trials in nephrology.

KW - Clinical trials

KW - Kidney

KW - Nephrology

KW - Pediatrics

UR - http://www.scopus.com/inward/record.url?scp=84873709240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873709240&partnerID=8YFLogxK

U2 - 10.1111/cts.12003

DO - 10.1111/cts.12003

M3 - Article

C2 - 23399084

AN - SCOPUS:84873709240

VL - 6

SP - 13

EP - 20

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

IS - 1

ER -